VERV beat EPS expectations by 47.66%
May 15, 2025, 10:37 AM
0.00%
What does VERV do
Verve Therapeutics, based in Boston, focuses on gene editing for cardiovascular diseases, employing 255 staff and going public on June 17, 2021. Its lead programs, VERVE-101, VERVE-102, and VERVE-201, target LDL-C-related genes.
Verve Therapeutics (VERV) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Verve Therapeutics's actual EPS was -$0.35, beating the estimate of -$0.67 per share, resulting in a 47.66% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.